|
Develop new safe and efficient treatment for autoimmune disease like Rheumatoid Arthritis (RA) |
|
|
Using an industrial approach with extended academic collaborations to identify, validate and document novel candidate drugs for treatment of Rheumatoid Arthritis and to partner with a larger company for clinical development, production and marketing. |
|
Redoxis
has a three-four year horizon to validate novel treatments for
autoimmune conditions like Rheumatoid Arthritis (RA), Multiple
Sclerosis (MS) and Inflammatory Bowels Disease (IBD). Redoxis use a
pharmacogenomic approach to visualize the mechanism of action of
developed treatments and to identify new therapeutic targets. This
successive progress of the R&D program will at the point of
preclinical safety documentation and early clinical trials result in
divestion of novel treatments of autoimmune disorders to larger
pharmaceutical or Biotech industry. During the development of the
company we are currently open for academic and industrial
collaborations and are currently looking for opportunities to
collaborate or in-license early projects in line with our research
focus.
|
|
|
